NP’s MIL was told 3-9 months, so if she lives pa

Quote:

---

NP’s MIL was told 3-9 months, so if she lives past the summer, well then, we’re getting somewhere.

---

She was given 1-3 months, not 3-9. I believe she received radiation, which extended her life a little longer so she could even survive long enough to qualify and get approval for leronlimab.

You make some valid points. However, I will counter two key differences or advantages of leronlimab. I haven't looked into NK much, so this is mostly lerolimab advantages. 1) it has a proven safety profile of over 800 HIV patients for long periods of time, some over 5 years without a single drug related SAE. 2) one of the key benefits of RP IMO is the trial measuring CTC levels. The entire purpose of of this is to expedite the results as surrogate endpoints for faster approval. With leronlimab's proven safety profile, they only need to show PFS......which the CTC test shows quickly of results are <5.

I'm not saying anything bad about NK......I actually hope for better drugs/treatments come to market for patients sake.....we never know when we may become one of them. If NK also has a similar surrogate endpoint like CTC, then this bodes well for them. I see they also have no drug related SAEs as others noted here, but not sure the duration and how many patients?

Please do your own due diligence. All my posts and comments are not to be considered investment advice.